{
  "id" : "hemeretic",
  "algorithm" : "eod_public",
  "version" : "3.3",
  "name" : "HemeRetic",
  "title" : "HemeRetic",
  "notes" : "9724, 9727, 9740-9742, 9749, 9762-9809, 9811-9820, 9831-9920, 9931-9993 \n* C700-C729, C751-C753 for 9749, 9766 (2018-2022 only) (See **Note 2**)\n\nC000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 1, 2 \n\nC000-C699, C739-C750, C754-C809: 9751, 9755-9759 \n\nC000-C440, C442-C689, C691-C694, C698-C809: 9930 \n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05:  https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 83 *Leukemia*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** \n* For the histologies and primary sites listed below, these have moved to the Brain, CNS Other, and Intracranial Gland schemas starting with 2023 diagnoses.\n* If you have one of these cases for 2018-2022, then this is the appropriate schema. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate schema\n  * **9749, 9766** \n    * **Brain**: C700, C710-C719\n    * **CNS Other**: C701, C709, C720-C725, C728-C729\n    * **Intracranial Gland**: C751-C753\n\n**Note 3:** **Other EOD Schemas with the listed histologies**\n* **Brain**: 9751, 9755-9759 (C700, C710-C719)\n* **CNS Other**: 9751, 9755-9759 (C701, C709, C720-C725, C728-C729)\n* **Intracranial Gland**: 9751, 9755-9759 (C751-C753)\n* **Lymphoma**: 9591 and Schema Discriminator 1: 3, 9 (C000-C440, C442-C689, C691-C694, C698-C809)\n* **Lymphoma Ocular Adnexa**: 9930 (C441, C690, C695-C696)\n\n**Note 4:** **Summary Stage** \n* Summary Stage is the only applicable staging system for this site/histology/schema.\n\n**Note 5:** **Histologies and Primary Sites** \n* See list of specific histologies below, effective for cases diagnosed 2010 and forward. \n* All primary sites (C000-C809) are included unless otherwise specified. \n\n**Note 6:** **Schema includes the preferred terms based on the 2024 WHO Classification of Tumours, Haematolymphoid tumors, 5th edition**\n\n* 9591 Splenic B-cell lymphoma/leukemia, unclassifiable (except C441, C690, C695-C696)\n* 9724: Systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL)\n* 9727: Blastic plasmacytoid dendritic cell neoplasm (BPDC)\n* 9740: Mast cell sarcoma (MSC)\n* 9741: Systemic mastocytosis with an associated hematological neoplasm (SM-AHN)\n* 9742: Mast cell leukemia (MCL)\n* 9749: Erdheim-Chester disease (ECD) (2021+ only) (except C700-C729, C751-C753 for 1/1/2023+)\n* 9750: ALK-positive histiocytosis\n* 9751: Langerhans cell histiocytosis, disseminated (except C700-C729, C751-C753)\n* 9755: Histiocytic sarcoma (except C700-C729, C751-C753)\n* 9756: Langerhans cell sarcoma (LCS) (except C700-C729, C751-C753)\n* 9757: Interdigitating dendritic cell sarcoma (IDCS) (except C700-C729, C751-C753)\n* 9758: Follicular dendritic cell sarcoma (FDCS) (except C700-C729, C751-C753)\n* 9759: Fibroblastic reticular cell tumor (except C700-C729, C751-C753)\n* 9762: Heavy chain diseases, NOS (HCD)\n* 9766: Lymphomatoid granulomatosis (LyG) grade 3 (2021+ only) (except C700-C729, C751-C753 for 1/1/2023+)\n* 9800 Leukemia, NOS\n* 9801: Acute undifferentiated leukemia\n* 9805: Acute leukemia of ambiguous lineage with other defined genetic alterations\n* 9806: Mixed-phenotype acute leukemia (MPAL) with *BCR::ABL1* fusion\n* 9807: Mixed-phenotype acute leukemia (MPAL) with *KMT2A-rearranged*\n* 9808: Mixed -phenotype acute leukemia, B/myeloid, NOS\n* 9809: Mixed-phenotype acute leukemia (MPAL), T/myeloid, NOS\n* 9811: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL], NOS\n* 9812: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 fusion*\n* 9813: B lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *KMT2A rearrangement*\n* 9814: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *ETV6::RUNX1 fusion*\n* 9815: B-lymphoblastic leukemia/lymphoma with high hyperdiploidy (B-ALL/LBL with high hyperdiploidy)\n* 9816: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with hypodiploidy (Hypodiploid B-ALL/LBL)\n* 9817: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *IGH::IL3 fusion*\n* 9818: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *TCF3::PBX1*\n* 9819: B-lymphoblastic leukemia/lymphoma [B-ALL/LBL] with *BCR::ABL1 like features* (BCR::ABL1-like B-ALL/LBL) (2021+ only)\n* 9820: Lymphoid leukemia, NOS\n* 9831: T-large granular lymphocytic leukemia (T-LGLL)\n* 9832: Prolymphocytic leukemia (PPL), NOS\n* 9833: Prolymphocytic leukemia, B-cell type (BLL) \n* 9834: T-cell prolymphocytic leukemia (T-PLL)\n* 9837: T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) \n* 9840: Acute erythroid leukemia (AEL)\n* 9860: Myeloid leukemia, NOS\n* 9861: Acute myeloid leukemia (AML), NOS\n* 9863: Chronic myeloid leukemia (CML), NOS\n* 9865: Acute myeloid leukemia with *DEK::NUP214 fusion*\n* 9866: Acute promyelocytic leukemia with *PML::RARA* fusion (APL with *PML::RARA*)\n* 9867: Acute myelomonocytic leukemia, NOS (AMML)\n* 9869: Acute myeloid leukemia with *MECOM rearrangement*\n* 9870: Acute basophilic leukemia\n* 9871: Acute myeloid leukemia with *CBFB::MYH11 fusion*\n* 9872: Acute myeloid leukemia, minimal differentiation\n* 9873: Acute myeloid leukemia without maturation\n* 9874: Acute myeloid leukemia with maturation\n* 9875: Chronic myeloid leukemia (CML), *BCR::ABL1 positive*\n* 9876: Myelodysplastic/myeloproliferative neoplasm with neutrophilia (MDS/MPN-N)\n* 9877: Acute myeloid leukemia with mutated *NPM1* (2021+ only)\n* 9878: Acute myeloid leukemia with *CEBPA mutation* (2021+ only)\n* 9879: Acute myeloid leukemia with mutated *RUNX1* (2021+ only)\n* 9891: Acute monocytic leukemia\n* 9895: Myelodysplasia-related acute myeloid leukemia (AML-MR)\n* 9896: Acute myeloid leukemia with *RUNX1::RUNX1T1*\n* 9897: Acute myeloid leukemia with *KMT2a rearrangement*\n* 9898: Myeloid leukemia associated with Down Syndrome (ML-DS)\n* 9910: Acute megakaryoblastic leukemia (AMKL)\n* 9911: Acute myeloid leukemia (megakaryoblastic) with *RBMI5::MRTFA*\n* 9912: Acute myeloid leukemia with *BCR::ABL1 fusion* (2021+ only)\n* 9920 Therapy-related myeloid neoplasms\n* 9930: Myeloid sarcoma (MS)  (except C441, C690, C695-C696)\n* 9931: Acute panmyelosis with myelofibrosis (APMF)\n* 9940: Hairy cell leukemia (HCL)\n* 9945: Chronic myelomonocytic leukemia, NOS (CMML)\n* 9946: Juvenile myelomonocytic leukemia (JMML)\n* 9948: Aggressive NK-cell leukemia (ANKL)\n* 9950: Polycythemia vera (PV)\n* 9961: Primary myelofibrosis (PMF)\n* 9962: Essential thrombocythemia (ET)\n* 9963: Chronic neutrophilic leukemia (CNL)\n* 9964: Chronic eosinophilic leukemia (CEL)\n* 9965: Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement\n* 9966: Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement\n* 9967: Myeloid/lymphoid neoplasm with *FGFR1* rearrangement\n* 9968: Myeloid/lymphoid neoplasm with *JAK2* rearrangement (2021+ only)\n* 9971 Post-transplant lymphoproliferative disorder, NOS (PTLD, NOS) (2018-2020, 2025+)\n* *Note:* 9971 is /1 for 2021-2024, moved back to /3 for 1/1/2025+\n* 9975: Myelodysplastic/myeloproliferative neoplasm, NOS, unclassifiable (MPN/MDS-U)\n* 9980: Myelodysplastic neoplasm with low blasts and single-lineage dysplasia (MDS-LB-SLD)\n* 9982: Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD) \n* 9983: Myelodysplastic neoplasm with increased blasts (MDS-IB)\n* 9985: Myelodysplastic neoplasm with low blasts, NOS (MDS-LB)\n* 9986: Myelodysplastic neoplasm with low blasts and 5q deletion (MDS-5q)\n* 9989: Myelodysplastic neoplasm, NOS\n* 9991: Refractory neutropenia (2018-2020 only, see code 9980/3 for 2021+)\n* 9992: Refractory thrombocytopenia (2018-2020 only, see code 9980/3 for 2021+)\n* 9993: Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (2021+)",
  "schema_selection_table" : "schema_selection_heme_retic",
  "schema_discriminators" : [ "year_dx", "discriminator_1", "behavior" ],
  "inputs" : [ {
    "key" : "year_dx",
    "name" : "Year of Diagnosis",
    "naaccr_item" : 390,
    "naaccr_xml_id" : "dateOfDiagnosis",
    "table" : "year_dx_validation",
    "used_for_staging" : true
  }, {
    "key" : "site",
    "name" : "Primary Site",
    "naaccr_item" : 400,
    "naaccr_xml_id" : "primarySite",
    "table" : "primary_site",
    "used_for_staging" : true
  }, {
    "key" : "hist",
    "name" : "Histology",
    "naaccr_item" : 522,
    "naaccr_xml_id" : "histologicTypeIcdO3",
    "table" : "histology",
    "used_for_staging" : true
  }, {
    "key" : "behavior",
    "name" : "Behavior",
    "naaccr_item" : 523,
    "naaccr_xml_id" : "behaviorCodeIcdO3",
    "table" : "behavior",
    "used_for_staging" : true
  }, {
    "key" : "discriminator_1",
    "name" : "Schema Discriminator 1",
    "naaccr_item" : 3926,
    "naaccr_xml_id" : "schemaDiscriminator1",
    "table" : "schema_discriminator_1_63995",
    "used_for_staging" : true,
    "metadata" : [ {
      "name" : "COC_REQUIRED"
    }, {
      "name" : "NPCR_REQUIRED"
    }, {
      "name" : "SSDI"
    }, {
      "name" : "CCCR_REQUIRED"
    }, {
      "name" : "SEER_REQUIRED"
    } ]
  }, {
    "key" : "age_dx",
    "name" : "Age at Diagnosis",
    "naaccr_item" : 230,
    "naaccr_xml_id" : "ageAtDiagnosis",
    "table" : "age_at_diagnosis_validation_65093",
    "used_for_staging" : false
  }, {
    "key" : "reporting_source",
    "name" : "Type of Reporting Source",
    "naaccr_item" : 500,
    "naaccr_xml_id" : "typeOfReportingSource",
    "table" : "type_of_reporting_source_76696",
    "used_for_staging" : false
  }, {
    "key" : "size_clin",
    "name" : "Tumor Size Clinical",
    "naaccr_item" : 752,
    "naaccr_xml_id" : "tumorSizeClinical",
    "default" : "999",
    "table" : "tumor_size_clinical_dna_64119",
    "used_for_staging" : false
  }, {
    "key" : "size_path",
    "name" : "Tumor Size Pathological",
    "naaccr_item" : 754,
    "naaccr_xml_id" : "tumorSizePathologic",
    "default" : "999",
    "table" : "tumor_size_pathological_dna_6742",
    "used_for_staging" : false
  }, {
    "key" : "size_summary",
    "name" : "Tumor Size Summary",
    "naaccr_item" : 756,
    "naaccr_xml_id" : "tumorSizeSummary",
    "default" : "999",
    "table" : "tumor_size_summary_dna_13275",
    "used_for_staging" : false
  }, {
    "key" : "nodes_pos",
    "name" : "Regional Nodes Positive",
    "naaccr_item" : 820,
    "naaccr_xml_id" : "regionalNodesPositive",
    "default" : "99",
    "table" : "nodes_pos_fpa",
    "used_for_staging" : false
  }, {
    "key" : "nodes_exam",
    "name" : "Regional Nodes Examined",
    "naaccr_item" : 830,
    "naaccr_xml_id" : "regionalNodesExamined",
    "default" : "99",
    "table" : "nodes_exam_76029",
    "used_for_staging" : false
  }, {
    "key" : "neoadjuvant_therapy",
    "name" : "Neoadjuvant Therapy",
    "naaccr_item" : 1632,
    "naaccr_xml_id" : "neoadjuvantTherapy",
    "default" : "0",
    "table" : "neoadjuvant_therapy_37302",
    "used_for_staging" : false,
    "metadata" : [ {
      "name" : "SEER_REQUIRED",
      "start" : 2021
    } ]
  }, {
    "key" : "neoadj_tx_clinical_response",
    "name" : "Neoadjuvant Therapy – Clinical Response",
    "naaccr_item" : 1633,
    "naaccr_xml_id" : "neoadjuvTherapyClinicalResponse",
    "default" : "0",
    "table" : "neoadj_tx_clinical_response_31723",
    "used_for_staging" : false,
    "metadata" : [ {
      "name" : "SEER_REQUIRED",
      "start" : 2021
    } ]
  }, {
    "key" : "neoadj_tx_treatment_effect",
    "name" : "Neoadjuvant Therapy – Treatment Effect",
    "naaccr_item" : 1634,
    "naaccr_xml_id" : "neoadjuvTherapyTreatmentEffect",
    "default" : "0",
    "table" : "neoadj_tx_treatment_effect_52725",
    "used_for_staging" : false,
    "metadata" : [ {
      "name" : "SEER_REQUIRED",
      "start" : 2021
    } ]
  }, {
    "key" : "eod_primary_tumor",
    "name" : "EOD Primary Tumor",
    "naaccr_item" : 772,
    "naaccr_xml_id" : "eodPrimaryTumor",
    "default" : "999",
    "table" : "extension_bci",
    "used_for_staging" : true
  }, {
    "key" : "eod_regional_nodes",
    "name" : "EOD Regional Nodes",
    "naaccr_item" : 774,
    "naaccr_xml_id" : "eodRegionalNodes",
    "default" : "888",
    "table" : "nodes_dna",
    "used_for_staging" : true
  }, {
    "key" : "eod_mets",
    "name" : "EOD Mets",
    "naaccr_item" : 776,
    "naaccr_xml_id" : "eodMets",
    "default" : "88",
    "table" : "mets_hna",
    "used_for_staging" : true
  }, {
    "key" : "ss2018",
    "name" : "SS2018",
    "naaccr_item" : 764,
    "naaccr_xml_id" : "summaryStage2018",
    "table" : "ss2018_hemeretic_3793",
    "used_for_staging" : false
  }, {
    "key" : "grade_clin",
    "name" : "Grade Clinical",
    "naaccr_item" : 3843,
    "naaccr_xml_id" : "gradeClinical",
    "default" : "8",
    "table" : "grade_clinical_18316",
    "used_for_staging" : true,
    "metadata" : [ {
      "name" : "COC_REQUIRED"
    }, {
      "name" : "NPCR_REQUIRED"
    }, {
      "name" : "SSDI"
    }, {
      "name" : "CCCR_REQUIRED"
    }, {
      "name" : "SEER_REQUIRED"
    } ]
  }, {
    "key" : "grade_path",
    "name" : "Grade Pathological",
    "naaccr_item" : 3844,
    "naaccr_xml_id" : "gradePathological",
    "default" : "8",
    "table" : "grade_pathological_73388",
    "used_for_staging" : true,
    "metadata" : [ {
      "name" : "COC_REQUIRED"
    }, {
      "name" : "NPCR_REQUIRED"
    }, {
      "name" : "SSDI"
    }, {
      "name" : "CCCR_REQUIRED"
    }, {
      "name" : "SEER_REQUIRED"
    } ]
  }, {
    "key" : "grade_post_therapy_clin",
    "name" : "Grade Post Therapy Clin (yc)",
    "naaccr_item" : 1068,
    "naaccr_xml_id" : "gradePostTherapyClin",
    "table" : "grade_post_therapy_clin_74830",
    "used_for_staging" : false,
    "metadata" : [ {
      "name" : "NPCR_REQUIRED"
    }, {
      "name" : "COC_REQUIRED"
    }, {
      "name" : "SSDI"
    }, {
      "name" : "SEER_REQUIRED"
    } ]
  }, {
    "key" : "grade_post_therapy_path",
    "name" : "Grade Post Therapy Path (yp)",
    "naaccr_item" : 3845,
    "naaccr_xml_id" : "gradePostTherapy",
    "table" : "grade_post_therapy_path_65729",
    "used_for_staging" : false,
    "metadata" : [ {
      "name" : "NPCR_REQUIRED"
    }, {
      "name" : "COC_REQUIRED"
    }, {
      "name" : "SSDI"
    }, {
      "name" : "CCCR_REQUIRED"
    }, {
      "name" : "SEER_REQUIRED"
    } ]
  }, {
    "key" : "jak2",
    "name" : "JAK2",
    "naaccr_item" : 3862,
    "naaccr_xml_id" : "jak2",
    "default" : "8",
    "table" : "jak2_80148",
    "used_for_staging" : false,
    "metadata" : [ {
      "name" : "COC_REQUIRED"
    }, {
      "name" : "SSDI"
    }, {
      "name" : "SEER_REQUIRED"
    } ]
  } ],
  "outputs" : [ {
    "key" : "naaccr_schema_id",
    "name" : "Schema ID",
    "naaccr_item" : 3800,
    "naaccr_xml_id" : "schemaId",
    "default" : "00830"
  }, {
    "key" : "derived_version",
    "name" : "Derived Version",
    "default" : "{{ctx_alg_version}}"
  }, {
    "key" : "ss2018_derived",
    "name" : "Derived Summary Stage 2018",
    "naaccr_item" : 762,
    "naaccr_xml_id" : "derivedSummaryStage2018",
    "table" : "derived_ss2018_hemeretic_89184",
    "default" : "9"
  }, {
    "key" : "derived_summary_grade",
    "name" : "Derived Summary Grade 2018",
    "naaccr_item" : 1975,
    "naaccr_xml_id" : "derivedSummaryGrade2018",
    "table" : "derived_grade_21945"
  } ],
  "mappings" : [ {
    "id" : "summary_stage_2018",
    "name" : "Summary Stage 2018",
    "tables" : [ {
      "id" : "derived_summary_grade_na_6690",
      "inputs" : [ "grade_path", "grade_clin" ],
      "outputs" : [ "derived_summary_grade" ]
    }, {
      "id" : "extension_bci",
      "inputs" : [ "eod_primary_tumor" ],
      "outputs" : [ "ss2018_t" ]
    }, {
      "id" : "nodes_dna",
      "inputs" : [ "eod_regional_nodes" ],
      "outputs" : [ "ss2018_n" ]
    }, {
      "id" : "mets_hna",
      "inputs" : [ "eod_mets" ],
      "outputs" : [ "ss2018_m" ]
    }, {
      "id" : "summary_stage_lymphoma_25139",
      "inputs" : [ "ss2018_m", "ss2018_n", "ss2018_t" ],
      "outputs" : [ "ss2018_derived" ]
    } ]
  } ],
  "involved_tables" : [ "neoadjuvant_therapy_37302", "tumor_size_clinical_dna_64119", "nodes_pos_fpa", "tumor_size_summary_dna_13275", "neoadj_tx_clinical_response_31723", "grade_post_therapy_clin_74830", "histology", "nodes_exam_76029", "schema_discriminator_1_63995", "age_at_diagnosis_validation_65093", "mets_hna", "derived_ss2018_hemeretic_89184", "behavior", "nodes_dna", "jak2_80148", "derived_grade_21945", "tumor_size_pathological_dna_6742", "schema_selection_heme_retic", "ss2018_hemeretic_3793", "type_of_reporting_source_76696", "summary_stage_lymphoma_25139", "primary_site", "neoadj_tx_treatment_effect_52725", "year_dx_validation", "derived_summary_grade_na_6690", "grade_post_therapy_path_65729", "extension_bci", "grade_clinical_18316", "grade_pathological_73388" ],
  "last_modified" : "2025-09-19T18:54:43.400Z",
  "on_invalid_input" : "CONTINUE"
}